This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Contents — quick navigation | ||
|---|---|---|
| A | Basic information | ICD-10: G41.2 | Special Copayment Reduction: V125 | Coverage period: 5 years |
| B | Synonyms | Focal impaired awareness SE, focal non-convulsive SE, psychomotor SE, temporal lobe SE, epileptic twilight state |
| C | Adult onset | Common in adults; a major complication of temporal lobe epilepsy; in new adult onset, stroke, tumor and autoimmune encephalitis should be ruled out first |
| S1 | History | From Gastaut's description in 1956 to the new ILAE 2017 classification |
| S2 | Causes | Temporal lobe epilepsy, stroke, autoimmune encephalitis, brain tumor, antiseizure medication withdrawal |
| S3 | Genetics | Associated with SCN1A, GRIN2A, LGI1; possibility of familial temporal lobe epilepsy |
| S4 | General epidemiology | The most common type of non-convulsive SE; about 20% of all SE |
| S5 | Pathophysiology | Sustained ictal discharges originating from temporal or frontal foci, with network propagation |
| S6 | Symptoms | Persistent clouding of consciousness, complex automatisms, reduced responsiveness; prolonged "twilight state" |
| S7 | Signs | Focal ictal discharges on EEG; temporal or frontal origin; repetitive automatisms |
| S8 | Screening | Immediate EEG; brain MRI; autoimmune antibodies; cerebrospinal fluid |
| S9 | Diagnosis | EEG essential; clinical–EEG correlation; Salzburg criteria; differentiation from ASE |
| S10 | Treatment | Benzodiazepine → valproic acid/levetiracetam → continuous midazolam infusion |
| S11 | Prognosis | Neurological sequelae when lasting more than 36 hours; dependent on the prognosis of the underlying disease |
| S12 | Prevention | Optimal treatment of underlying temporal lobe epilepsy; early immunotherapy for autoimmune encephalitis |
| S13 | References | 10 key references |
Complex Partial Status Epilepticus (CPSE) is a condition in which focal-onset seizures with impaired consciousness persist. In 1956 Gastaut first described this condition using the term "psychomotor status epilepticus." He described a clinical syndrome of clouded consciousness, automatisms and electrical discharges lasting from hours to days, and defined it as an independent clinical entity distinct from tonic-clonic SE.
In 1978 Engel, Ludwig and Fetell analyzed CPSE of temporal lobe origin in detail and presented the correlation between EEG and clinical features. With complex partial seizures established as an independent category in the 1981 ILAE seizure classification, the concept of CPSE was also formalized. In 1991 Treiman used an EEG severity scale to describe the stepwise transition from generalized convulsive SE to subtle SE, and similarly observed that CPSE also changes from clinically obvious symptoms to increasingly subtle ones.
Clinically, CPSE is easily confused with psychiatric conditions (dissociation, delirium), metabolic encephalopathy, transient global amnesia and others, so diagnosis was historically often delayed. Since the 1990s, as awareness of non-convulsive SE increased, the diagnostic rate of CPSE has greatly improved along with advances in long-term EEG monitoring. In the new 2015 ILAE classification of SE, CPSE was renamed "NCSE with impaired consciousness, focal onset." In the 2017 ILAE seizure classification, the former "complex partial seizure" was also renamed "focal impaired awareness seizure," and CPSE is likewise understood within this framework.
CPSE is a persistent state of focal seizures originating in the temporal or frontal lobe. Its causative conditions overlap considerably with those of convulsive SE, but focal brain lesions are the main cause.
The genetic background of CPSE is determined by the genetic characteristics of the underlying temporal or frontal lobe epilepsy.
Mutations in the LGI1 (Leucine-rich glioma inactivated 1) gene cause autosomal dominant lateral temporal lobe epilepsy (ADLTE). The LGI1 protein binds ADAM22/ADAM23 at the synapse to regulate AMPA receptor function, and mutations cause hyperexcitability. LGI1 antibody-associated autoimmune encephalitis is an important cause of SE of temporal lobe origin.
| Gene | Associated syndromes | Features |
|---|---|---|
| LGI1 | Familial temporal lobe epilepsy, autoimmune encephalitis | AMPA receptor regulation; autonomic aura, deja vu |
| GRIN2A | Sleep-related centrotemporal spikes | NMDA receptor GluN2A subunit; frontal lobe SE possible |
| SCN1A | Dravet syndrome | Seizures of temporal lobe origin possible; triggers febrile SE |
| DEPDC5 | Familial focal epilepsy | mTOR regulation; associated with cortical dysplasia |
Whole-genome analysis is playing an increasingly important role in patients with CPSE of unknown cause, and in particular the discovery of de novo mutations contributes to prognosis and to setting the direction of treatment.
CPSE is the most common type of non-convulsive SE (NCSE), reportedly accounting for about 20–35% of all SE patients. Among patients with impaired consciousness visiting the emergency department, the proportion with non-convulsive SE reaches about 8–37% when EEG monitoring is performed.
Precise epidemiological data on the incidence of CPSE are limited, but considering the overall incidence of SE (10–41/100,000), the annual incidence of CPSE is estimated at 5–15 per 100,000 population. It can occur at any age but is mainly observed in adulthood (ages 20–60), when temporal lobe epilepsy is most common.
The frequency of non-convulsive SE in intensive care unit (ICU) patients is reported at about 8–20% in continuous EEG (cEEG) monitoring studies. A higher proportion (up to 34%) is observed in neurological ICU patients. CPSE can occur alone or after convulsive SE; in the latter case it forms part of "subtle SE," in which electrographic seizures persist even after the convulsions have disappeared.
CPSE is a condition in which ictal discharges originating from a specific focus in the temporal or frontal lobe are sustained or repeated, causing impaired consciousness.
Seizures originating in the hippocampus, amygdala and parahippocampal cortex propagate along mesial temporal structures. A mechanism is triggered by which the excitatory network of the mesial temporal lobe maintains self-reinforcing seizure activity. Hippocampal hyperexcitability and disinhibition are central, and this is associated with the formation of hippocampal sclerosis after recurrent SE.
Compared with temporal lobe origin, CPSE of frontal lobe origin has less characteristic EEG findings and is often difficult to confirm without intracranial electrodes. Frontal hypermotor automatisms, short seizure cycles and impaired consciousness are characteristic. It can propagate to both hemispheres through frontotemporal connections.
Progressive internalization of GABA-A receptors is also observed in CPSE, causing benzodiazepine resistance over time. Overactivation of glutamatergic NMDA and AMPA receptors reinforces sustained seizure propagation, and excitotoxicity, a mechanism of neuronal injury, is activated in prolonged CPSE.
CPSE is called the "epileptic twilight state" and is characterized by clouding of consciousness without convulsions.
CPSE tends to show more complex automatisms, more severe impairment of consciousness and more bizarre behavioral changes than ASE. Focal neurological symptoms related to the seizure onset zone (temporal lobe: oral automatisms, sensation of fear; frontal lobe: hypermotor automatisms, brief seizures) are helpful.
Todd's paralysis (postictal focal paralysis) may be observed after CPSE ends. Focal neurological abnormalities (hemiparesis, speech disturbance) may appear in association with an underlying structural lesion. Head/eye deviation appears toward the side opposite the seizure onset zone.
This is the standard approach for early screening of CPSE in patients with impaired consciousness.
Immediate EEG is performed in patients with impaired consciousness of unknown cause. Because CPSE cannot be diagnosed clinically alone, EEG is essential. Continuous EEG (cEEG) monitoring is recommended in ICU patients.
Brain MRI (including FLAIR, DWI, T2 and gadolinium contrast) to identify the cause of focal onset. In the acute phase, seizure-related FLAIR changes may be observed in the temporal lobe (especially the hippocampus). DWI hyperintensity reflects seizure-related diffusion restriction and may be reversible after the seizure ends.
In new-onset CPSE in adults, autoimmune encephalitis antibodies (anti-NMDA receptor, LGI1, CASPR2, GABA-B, AMPA receptor antibodies, etc.) are tested in serum and cerebrospinal fluid. Starting empirical immunotherapy before the results are available is often recommended.
Cell count, protein and glucose tests to exclude meningitis and encephalitis. Includes HSV PCR, bacterial culture and autoimmune antibody testing.
CPSE is diagnosed through integrated evaluation of the clinical presentation and EEG.
The 2013 Salzburg criteria divide non-convulsive SE into "definite" and "possible." In CPSE, when focal ictal discharges are confirmed on EEG and accompanied by clinical impairment of consciousness, "definite NCSE" is diagnosed. Confirmation of EEG improvement and clinical improvement after antiseizure medication has diagnostic value.
| Differential diagnosis | Distinguishing points |
|---|---|
| Absence status epilepticus (ASE) | Generalized 3 Hz spike-and-wave; simple automatisms; shorter seizure cycles |
| Transient global amnesia (TGA) | Predominantly memory impairment; repetitive questioning; normal EEG; recovery within 24 hours |
| Simple partial seizure SE | Consciousness preserved; only motor/sensory/autonomic symptoms persist |
| Herpes encephalitis | Fever, prodromal symptoms; temporal lobe FLAIR changes on MRI; confirmed by PCR |
| Metabolic encephalopathy | Slowing or triphasic waves without EEG ictal discharges; underlying metabolic abnormality |
CPSE is less urgent than convulsive SE, but neurological damage can occur if it persists for a long time, so active treatment is required.
The prognosis of CPSE is determined by the underlying cause, the duration of SE and the promptness of treatment.